Review Article

Int Jou Hea Bio Sci, 5(1), 2024, 6-12

International Journal of Health care and Biological Sciences

Content available at www.saap.org.in Online ISSN: 2582-7499

Open Access

CONCISE SUMMARY: HEMOCHROMATOSIS ALONG WITH ITS CURE

Yash Srivastav[1*], Ajeet Singh[2], Mohd Faijan Mansoori[3], Madhaw Kumar[4]

[1,3]Azad Institute of Pharmacy & Research, Lucknow, U.P, India.

[2,4]Goel Institute of Pharmacy & Sciences (GIPS), Lucknow, U.P, India.

Article History

Received on: 12-01-2024
Revised on: 22-01-2024
Accepted on: 30-03-2024

Abstract

A condition known as hemochromatosis results in excessive iron deposition, which damages several organs. Hemochromatosis affects the liver, pancreas, heart, thyroid, joints, skin, gonads, and pituitary among other organs. Famous diagnostician and teacher Dr. Armand Trosseau published the first medical description of a patient with hemochromatosis in a French pathology paper in 1865.Hemochromatosis is a well-defined illness that can be brought on by mutations in any gene that restricts iron entry into the blood. It is typified by normal iron-driven erythropoiesis and hazardous iron accumulation in parenchymal cells of essential organs. When Feder et al. found in 1996 that a mutation in HFE caused hereditary hemochromatosis, it was a significant discovery for the field of hemochromatosis research.Systemic iron excess of hereditary origin resulting from a hepcidin deficiency, including reduced hepcidin-ferroportin binding activity or production, is known as hemochromatosis. A correct diagnosis of this illness is frequently challenging due to the wide range, lack of specificity, and vagueness of its signs and symptoms. The early warning signs and symptoms include arthralgia, weakness, weight loss, and stomach pain.In this review study, we discuss the pathophysiology, epidemiology, symptoms, and aetiology of hemochromatosis.

Keywords: Hemochromatosis, Epidemiology, Symptoms, Pathophysiology, Medication

***Corresponding Author**
Yash Srivastav

ORCID Id: https://orcid.org/0009-0008-5017-6529

DOI: https://doi.org/10.46795/ijhcbs.v5i1.574

Introduction

Hemochromatosis is a rare genetic illness, or maybe a set of disorders, characterized by persistently high levels of iron absorption from diet. The body's iron reserves consequently usually rise noticeably. Damage to the organ systems where iron has been pathologically deposited causes the disease's clinical manifestations. These organ systems most frequently include the liver (cirrhosis), pancreas (diabetes mellitus), anterior pituitary (gonadotropin shortage), heart (cardiomyopathy), and joints (arthritis). One of the most prevalent genetic illnesses affecting White people is hemochromatosis [1]. The condition known as hemochromatosis is linked to iron overload deposits that result in various organ dysfunctions. Iron intake is normally strictly controlled since the body cannot eliminate excess iron. High pathologic amounts of iron buildup in the body result in hemochromatosis. Hemochromatosis has been dubbed "bronze diabetes" because of the skin colouringand pancreatic illness it causes. For Caucasians, the most prevalent autosomal recessive disorder is hereditary hemochromatosis [2]. A potentially significant public health endeavour is the identification of iron overload situations, as iron-induced organ damage can often be prevented with prompt diagnosis and treatment. While iron overload can have a variety of causes, the majority of cases in the North American population are caused by a well-known genetic disorder called "hereditary hemochromatosis." This condition is passed down as an autosomal recessive trait and is caused by a mutation of the gene HFE, which is found on the short arm of chromosome 6.The commonest mutation (C282Y) is caused by a G to A missense substitution, which causes cysteine to take the place of tyrosine at amino acid

position 282 in the protein produced by the HFE gene. The HH condition is defined genetically by this mutation. The homozygous C282Y mutation, when fully expressed, causes a progressive accumulation of parenchymal iron in various body organs, mainly the liver, pancreas, heart, joints, and endocrine tissue, ultimately resulting in structural and functional damage to those organs [3–5]. An autosomal recessive condition called hereditary hemochromatosis (HH) causes iron excess in several organs, most notably the liver. Trousseau (1889) initially defined the monoallelic genetic illness as a trio consisting of skin hyperpigmentation, cirrhosis, and glycosuria. Von Recklinghausen was the first to use the word "hemochromatosis" (1889). Although the body's iron reserves are rising and hereditary hemochromatosis patients have an abnormally low iron status, enterocytes nevertheless promote the excessive absorption of iron from food, which results in iron overload. Simon (1977) was the first to describe the intimate relationship between HH and the histocompatibility antigen HLA-A3 on the short arm of chromosome 6.In populations of European descent, almost 80% of HH patients are homozygotes for a single C282Y mutation in the HFE gene or compound heterozygotes for both C282Y and H63D mutations.However, frequencies of C282Y are almost nonexistent in most populations of Asia, the Indian subcontinent, Africa, Australasia, and the Americas (Hanson et al. 2001). Within the Russian population, homozygosity for C282Y is only observed in 5% of patients who exhibit biochemical and clinical indications of HH.There are remarkably few documented examples of idiopathic hemochromatosis in India [6]. Hemochromatosis prevalence cannot be precisely determined in the absence of a direct disease marker; instead, it must be estimated using extensive iron overload surveys. In the absence of other known reasons, such as high iron consumption, transfusions, enhanced erythropoiesis, and other potential diagnoses to be explored later, iron overload is assumed to reflect hemochromatosis. By using haplotype and allele sharing in family research, more cases of hemochromatosis can be found once an index case has been found [7,8].

Categorization of States with Iron Overload

Although all iron overload symptoms are evaluated in this background discussion, HH is the main topic of discussion. HFE is connected to most causes of HH. Nonetheless, a tiny number of family cases of HH have surfaced recently, in which no HFE gene mutation was found despite the patients meeting all diagnostic phenotypic criteria.An unknown fraction of the 10% of non-HFE mutations in families with conventional HH may be explained by alternative gene mutations, which are the subject of growing information from isolated case studies. The path for HFE-related HH, non-HFE-related HH, and different types of secondary iron overload is provided by the HH diagnostic algorithm that was endorsed by the American Association for the Study of Liver Diseases and its sister gastroenterology groups [9–11].

Epidemiology

With an incidence of 1 in 300 to 500 people, hereditary hemochromatosis is the most prevalent autosomal recessive condition among white people [5]. While types 2, 3, and 4 of hereditary hemochromatosis are found worldwide, type 1 is primarily found in individuals with northern European ancestry. Hemochromatosis is equally common in Europe, Australia, and other Western nations where the proportion of individuals descended from Celtics is higher. Patients of African descent experience it less frequently. Compared to Blacks, White people are six times more likely to get the illness.Men are affected by hemochromatosis two to three times more frequently than women. Men to women are projected to be divided at a 1.8:1 to 3:1 ratio. The symptoms of hemochromatosis in women manifest later in life than in men because of the blood loss and iron excretion that accompany menstruation. The disease typically manifests in the fifth decade in men; in women, it frequently manifests in the sixth decade. In contrast, people between the ages of 10 and 30 may develop juvenile hemochromatosis [7,8]. In India, primary hemochromatosis is not common. Seventeen of the 236 Chandigarh patients with chronic liver disease exhibited clinical and biochemical signs of primary iron overload. Twelve out of seventeen patients had liver biopsies, and the results indicated grade 3 to 4 parenchymal iron overload, which is consistent with hemochromatosis. Only 24 individuals from a different series of 249 New Delhi patients with biopsy-proven nonalcoholic cirrhosis had transferrin saturation greater than 60%, and none of them exhibited grade 3 to 4 parenchymal iron in the liver.3. Nevertheless, 13 patients with primary iron excess were discovered in a different sample of 496 cirrhosis patients from Lucknow [12].

Etiology

In hereditary hemochromatosis, retained iron is mostly deposited in the parenchymal cells; in trans-fusional hemochromatosis, it is largely deposited in the reticuloendothelial cells. Hemostasis is the form in which the extra iron is stored in the cells. This ultimately results in the death of the cells and their replacement by a fibrous buildup, which damages or impairs the function of the organs. When a homozygote's hemochromatosis gene (HFE) protein is mutated, hereditary hemochromatosis results. Despite a normal dietary iron intake, an enhanced absorption of iron is caused by a mutation in the HFE gene. The two most prevalent mutations in the HFE gene are C282Y and H63D.Type 1 (HFE-related): This is the traditional form of hereditary hemochromatosis, inherited by autosomal recessive inheritance and present in people all over the world. Both white people and non-white people can have type 2a (mutations of the hemojuvelin gene) or type 2b (mutations of the hepcidin gene)

autosomal recessive disorders. It often starts between15 and 20 years sold.Type 3: Transferrin receptor-2 gene mutations: This autosomal recessive disorder affects both white people and non-white people. It starts between ages 30 and 40.Ferroportin gene mutations, or type 4, are an autosomal dominant disorder that affects both white people and non-white people. The age range for its onset is 10–80 [13–15].

Symptoms and Signs

A correct diagnosis of this illness is frequently challenging due to the wide range, lack of specificity, and vagueness of its signs and symptoms. The early warning signs and symptoms include arthralgia, weakness, weight loss, and stomach pain. Patients can additionally experience arthritis, dyspnea or shortness of breath, or gonadal failure symptoms such as amenorrhea, early menopause, low libido, and impotence as their iron accumulation worsens. Many organs' parenchymal cells store iron; the liver is one of the main locations, and afterwards the heart and pancreas. Arthritis, abnormal liver function (elevated transaminase, clinical liver disease), glucose intolerance, diabetes, hypogonadism, hypopituitarism, cardiomyopathy (enlarged heart), arrhythmia (abnormal heartbeat), cirrhosis, liver cancer, heart failure, and grey or bronze skin pigmentation resembling a suntan are conditions linked to advanced stages of hemochromatosis. The long list of symptoms makes it clear that hemochromatosis can be very challenging to diagnose. The majority of severe hemochromatosis side effects are also prevalent main illnesses. Therefore, unless hemochromatosis is properly searched for, a diagnosis may go unnoticed even in advanced stages. In light of the low number of cases that have been diagnosed in Grand Cayman and some US hospitals, one must question whether doctors in the Cayman Islands (Territory of Britain) and around the world are actively screening for hemochromatosis or whether they are misinterpreting its symptoms for other prevalent primary disorders. When I talked to a few doctors, most of them had a hazy understanding of hemochromatosis. The majority saw that there was "too much iron in the blood." But none of them could recall any indications, symptoms, or therapies when questioned about them. Many people report feeling better after extra iron is eliminated, even though some hemochromatosis symptoms are unrelated [16]. When iron levels in the body reach harmful levels, which usually happen between the ages of 40 and 60, the symptoms of hereditary hemochromatosis start to show. This is because the accumulation of iron takes many years to reach the point at which symptoms appear. Women typically have symptoms later in life than males, usually after menopause, since they lose more iron than men do due to menstruation, pregnancy, and lactation. The term "penetrance" describes the probability that a certain gene would genuinely result in disease. Therefore, a person who has two mutant HFE genes does not always have to have symptoms; in fact, they may live a symptom-free life. Early research on hemochromatosis defined it using a combination of clinical indications and self-reported symptoms; the results showed estimates of clinical penetrance ranging from 40% to 70%. On the other hand, clinical penetrance estimates ranging from 1% to 50% have been published in more recent investigations that defined hemochromatosis using objective laboratory tests or clinical symptoms.Further research is required to completely understand the role of genetic and environmental factors that may affect penetrance, as there are still discrepancies in penetrance estimations.Merely a few individuals possessing HFE mutations will experience increased transferrin saturation (TS). Only a portion of these will have high serum ferritin (SF), and only a smaller portion will experience hemochromatosis symptoms. Only a few of the symptomatic individuals will have clinical indicators typical of hemochromatosis. Therefore, only those whose symptoms and signs may be linked to known iron overload are eligible for a diagnosis [16,17].

Pathophysiology

Hemochromatosis affects the liver, pancreas, heart, thyroid, joints, skin, gonads, and pituitary among other organs. Hemochromatosis-related pathology is accelerated by excessive alcohol consumption and viral hepatitis, particularly in terms of liver and pancreatic damage. Seventy per cent of hemochromatosis patients have cirrhosis. Hepatocellular carcinoma, a major cause of death, has a noticeably higher incidence in these people.The main symptom of pancreatic iron deposition is diabetes. For patients who exhibit symptoms, the incidence of diabetes is almost 50%, and heterozygotes with hereditary hemochromatosis are at higher risk.Without destroying the joints, arthroscopy presents as joint pain. This condition presents exactly like degenerative joint disorder, however the synovial fluid contains crystals of calcium pyrophosphate. After iron store normalcy, it can still advance.Iron buildup in the conduction system cells and cardiac muscle fibres causes cardiac symptoms [18]. It is possible for there to be anomalies in the electrocardiogram before there is actual heart failure. Congestive heart failure brought on by cardiac arrhythmias and dilated cardiomyopathy is the cause of the symptoms. Iron reserves can occasionally be removed to reverse left ventricular failure. Iron-induced hypothalamic or pituitary failure impairs the release of gonadotropin hormone, which leads to hypogonadism and impotence. Melanin and iron deposition both contribute to skin hyperpigmentation. Usually, it doesn't happen before the iron stores rise to five times their typical levels. Macrophages that are iron-overloaded may have compromised phagocytosis and weakened immunity, which raises the chance of contracting infections from Vibrio vulnificus, Yersinia enterocolitica, and Listeria. Hemochromatosis patients should avoid handling or consuming raw shellfish since Vibrio vulnificus might

cause sepsis. Hypothyroidism is brought on by iron buildup in the thyroid gland. Men with hemochromatosis have an 80-fold increased incidence of hypothyroidism compared to healthy individuals.Clinical signs of iron accumulation in the parathyroid and adrenal glands are infrequent [18]. Hemochromatosis is most commonly caused by an inherited autosomal recessive disorder with varying penetrance. We refer to this illness as primary hemochromatosis. When the HFE protein is mutated in homozygotes, hereditary hemochromatosis results. Despite a normal dietary iron intake, a mutation in the HFE gene results in enhanced iron absorption. Hepcidin, an iron-regulating hormone, is produced under regulation by the HFE protein. The amount of hepcidin that the liver produces controls the amount of iron that is taken up from food and expelled from the body's storage facilities. It appears that HFE's typical role is to regulate cells' uptake of iron via interacting with transferrin receptors. Ninety per cent of instances of hereditary hemochromatosis in people of Northern European origin are caused by two mutations in the HFE gene.Iron excess can occur in heterozygotes despite possible abnormalities in clinical indicators of iron metabolism. For reasons that are still unclear, heterozygotes do have a higher risk of diabetes than the overall population. Erythropoietic hemochromatosis, a disorder caused by the patient absorbing too much iron as a result of creating too many red blood cells, is one of the causes of secondary hemochromatosis. This frequently happens as a result of an underlying illness that shortens the life of red blood cells by making them more brittle. The iron from the damaged cells is deposited in the bodily tissues. Patients who get repeated, often ongoing, red blood cell transfusions experience the same mechanism. Iron overload can also result from other, less prevalent disorders like porphyria cutanea tarda. Unlike the hereditary type of the disorder, erythropoietic hemochromatosis is present in a wider range of races and follows the prevalence of the underlying disease (e.g., thalassemia, spherocytosis). Last but not least, hemochromatosis can also result from consuming too much iron. This is what happens historically when beer is served from steel drums. Some nutritional supplements sold over the counter can cause iron overloads, both unintentional and purposeful [19–22].

Diagnosis

As per the current clinical guidelines, individuals who exhibit any unexplained signs or symptoms associated with hemochromatosis, as well as those who have abnormal blood tests consistent with hemochromatosis, porphyria, hepatitis, or other liver diseases, should be tested for hemochromatosis. People who have a family member with the illness should be particularly checked for this hereditary sickness because they are more likely to experience iron overload and make a great target population for focused preventative initiatives.To determine iron overload, a variety of laboratory techniques are available to assess blood iron levels. Serum iron (SI), total iron-binding capacity (TIBC), unsaturated iron-binding capacity (UIBC), transferrin saturation (TS), and serum ferritin (SF) are among the biochemical assays. To diagnose hereditary hemochromatosis, the Centers for Disease Control and Prevention (CDC) have developed a three-step testing technique. involving the confirmation of the hemochromatosis diagnosis, a blood ferritin test, and a transferrin saturation test.A blood protein called transferrin counts the amount of iron that is taken up by the intestines and moves it from one place to another. Iron becomes more saturated in transferrin proteins when iron absorption is excessively high. Therefore, a higher TS value indicates a higher rate of iron absorption. The transferrin saturation test (TS) is a biochemical indicator of iron overloading that is sensitive and reasonably priced.It is crucial to remember that a number of things might artificially raise fasting transferrin saturation (TS) readings. These include the use of vitamin C, iron-containing dietary supplements, pharmaceutical iron, and estrogen preparations. It should be advised to people not to use these products for 24 hours before a fasting blood sample. Conversely, illnesses such as cancer, inflammation, liver disease, and colds can erroneously lower TS readings. When someone exhibits symptoms that align with hemochromatosis, pathologic blood loss or a history of frequent blood donations should be taken into consideration as explanations for normal iron status. Serum ferritin testing should be done on those with increased TS values, along with any further workup that may be required. Iron is stored by the protein ferritin, as was previously explained. When too much iron is absorbed, the body produces more ferritin in the serum. Thus, the body's iron reserves are reflected in serum ferritin levels. It is significant to highlight that SF levels may rise in the presence of inflammatory or viral processes, cancer, and other underlying diseases because serum ferritin is also an acute phase reactant impacted by these processes. The final test is usually necessary prior to the diagnosis of hemochromatosis and entails obtaining further biochemical evidence of iron excess. There are three methods to obtain this confirmation: liver biopsy directly, HFE genotyping, and quantitative phlebotomy indirectly [16]. Serum ferritin concentration or serum transferrin saturation should be measured as the first step in the study. It should be mentioned that in patients with erythropoietic hemochromatosis, transferrin saturation testing may not be as useful in detecting iron overload. Irritating situations can have an impact on ferritin specificity. Additional testing should be done if a woman's ferritin level is more than 200 mcg/L a man's is more than 300 mcg/L, or if a woman's transferrin saturation is more than 40% or 50% in a man. Additional genetic testing for the genes C282Y and H63D should be acquired, as the HFE mutation is common in the United States. In more than 90% of cases, genetic testing for these mutations will

validate the diagnosis. When identifying organ involvement, radiography can be used, and echocardiography can rule out cardiomyopathy. Increased pulmonary vascular markings and cardiomegaly may be seen on a chest radiograph. Hepatic MRI is a non-invasive technique for determining iron concentration in the liver. The most accurate and precise test for determining the iron level of the liver and evaluating liver damage is a liver biopsy. Perls Prussian blue staining histological investigation reveals a characteristic pattern of iron deposits predominantly in hepatocytes and biliary epithelial cells, with minor involvement of Kupffer cells. Indicators for liver biopsies include the following: elevated liver enzymes in a hemochromatosis patient with a diagnosis. serum ferritin concentrations above 1000 mcg/L.Although most patients have raised aminotransferase levels and elevated liver enzymes, these levels are typically not more than twice those of normal. It is necessary to examine fasting blood glucose levels for diabetes. Blood tests involving glycosylated haemoglobin may not be accurate in individuals with elevated red cell turnover. Patients with elevated ferritin levels also require echocardiography to assess cardiomyopathy, hormone levels to assess hypogonadism, and bone densitometry to assess osteoporosis. Hemochromatosis sufferers' first-degree relatives should be screened by genetic testing [23–27].

Medication-Based Care

The body's iron content and related symptoms at the time of diagnosis are major factors in the initial and long-term therapy of hemochromatosis. Hemochromatosis-related disorders, such as diabetes mellitus and liver disease, require distinct management in addition to treatment. The most widely used form of management and treatment is phlebotomy. The way phlebotomy operates is by inducing the bone marrow to produce new red blood cells while removing the old ones. To create additional haemoglobin, iron is taken from the body's iron reserves. As a result, phlebotomy lowers the patient's iron level and helps raise it back to a safe range. Normalizing iron storage during the first de-ironing phase entails weekly blood draws by phlebotomy until mid-hypoferritinemia develops. In other words, ferritin should be 20 ng/ml. Usually, this stage takes three months to a year. Patients differ in the amount of blood that needs to be extracted. A unit (500 ml) of blood is normally removed once a week, although smaller people (less than 110 lbs), the elderly, people with anaemia, and people with heart and lung issues can only handle 250 ml of blood removal every week. Throughout treatment, each patient must be closely observed. Anaemia could occur from an overly vigorous course of treatment. Phlebotomy is the standard treatment for primary hemochromatosis. Iron toxicity, the body's primary mobilizer of iron, can be reduced by removing red blood cells. For patients to return to normal iron levels, 50–100 500 mL phlebotomies can be necessary. Typically, phlebotomy is done once or twice a week. Phlebotomy is needed for life, but less frequently—typically three to four times a year—once iron levels have returned to normal. A ferritin level of fewer than 50 mcg/L is the desired result. Phlebotomy-assisted iron removal improves skin pigmentation, weariness, and insulin sensitivity, but not cirrhosis, hypogonadism, or arthropathy [28–30].In this scenario, alcohol should be strictly banned as it can hasten pancreatic and liver poisoning. Phlebotomy seldom reverses end-organ damage that already exists. It is recommended to treat related end-organ dysfunction with insulin for pancreatic dysfunction. Hemochromatosis has minimal mortality or morbidity if it is identified early and treated to avoid end-organ damage. However, if there has been significant end-organ damage, patients rarely survive for longer than two years following the diagnosis. Chelation is more beneficial in erythropoietic hemochromatosis, when phlebotomy is usually not an option, even though it is less successful in hereditary hemochromatosis. One intravenous iron-chelating agent is deferoxamine. Oral iron chelators include deferasirox and deferiprone. When it comes to the mobilization and excretion of iron, they are all equally effective [31,32]. Sometimes phlebotomy and erythropoietin are used to force iron mobilization while maintaining hemoglobin concentration. Individuals with advanced liver disease might be suitable candidates for liver transplantation. Research has indicated that patients with iron overload illnesses undergoing liver transplantation had reduced survival rates when compared to non-hemochromatosis reasons. Since around 30% of hemochromatosis-related deaths are due to HCC, all hemochromatosis patients will receive surveillance, including six-monthly ultrasounds and measurements of alpha-fetoprotein [33]. Appropriate patient management necessitates post-treatment monitoring. For the duration of the patient's life, phlebotomy should be used to maintain ferritin levels between 25 and 50 ng/ml.Patients with other acquired or heritable anaemias that prevent bleeding may benefit from chelation therapy. The pharmacological elimination of metals by substances that bind to metal and allow it to be eliminated in urine is known as iron chelation. However, intravenous deferoxamine, also known as desferrioxamine or Desferal, is the only pharmacological iron-chelating agent that has been licensed by the FDA for use in humans. This method isn't as effective as phlebotomy in its entirety, thus it should only be employed in dire circumstances.There are home remedies and lifestyle changes that can lower the risk of hemochromatosis-related problems. Hemochromatosis patients should stay away from iron-containing multivitamins and supplements since they may raise their iron levels even more. Alcohol use should be restricted by those who have the illness in order to mitigate the effects of liver cirrhosis. They should also limit their intake of red meat, which is high in iron, and avoid vitamin C, which promotes the absorption of iron from the gastrointestinal

tract. Because people with hemochromatosis are prone to infections, particularly those brought on by certain bacteria found in raw shellfish, they should refrain from consuming raw shellfish. Additionally, consuming more calcium and tea with high tannin content, which hinder iron absorption, may help reduce the body's iron buildup [16,34].

Discussion and Conclusion

Our review articles begin with an overview of hemochromatosis, including its various causes, epidemiology, symptoms, pathophysiology, and alternative therapy. According to our statistics, natural and non-pharmacological supplements have no negative effects and provide a reasonable long-term outcome, while medications treat, but not entirely. The field of hemochromatosis treatment needs more randomized controlled trials. In the future, we would like to do a preliminary investigation of hemochromatosis. With the help of our colleagues, future counseling-based research in our country or state will assess the physical and mental health of patients and produce more accurate data on hemochromatosis and its treatment.

Ethical Statement

A pharmacist strives to improve each patient's health in a discrete, considerate, and compassionate manner.

Acknowledgement

The authors would like to thank, Azad Institute of Pharmacy & Research, Lucknow, U.P, India, Lucknow, Uttar Pradesh, India for extending their facilities.

Conflict of Interest

The authors attest that they are free of any known financial or personal conflicts of interest that would taint the findings of this study.

Informed Consent

Using websites, review articles, and other sources to produce research content.

References

1. 1. Smith LH. Overview of hemochromatosis. West J Med. 1990;153(3):296–308.
2. 2. Rawla P, Health S. Hemochromatosis Hemochromatosis Pathophysiology. 2019;(February).
3. 3. Tavill AS, Adams PC. A diagnostic approach to hemochromatosis. Can J Gastroenterol. 2006;20(8):535–40.
4. 4. O'Neil, Jillian, and Lawrie Powell. "Clinical aspects of hemochromatosis." Seminars in liver disease. Vol. 25. No. 04. Copyright© 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA., 2005. 2005;25(04):17–9.
5. 5. A novel MHC class I- Like gene is mutated in patients with hereditary haemochromatosis. © 199 6 Nature Publishing Group httpwww.nature.comnaturebiotechnology.
6. 6. Poddar S. Hereditary Hemochromatosis-Special Reference to Indian Scenario. Int J Hum Genet. 2006;6(1):73–9.
7. 7. Majul CA. Edwards, Corwin Q., et al. "Prevalence of hemochromatosis among 11,065 presumably healthy blood donors." New England Journal of Medicine 318.21 (1988): 1355-1362. 1988;1(2):12–7.
8. 8. Gabetta. Hallberg, L., E. Björn-Rasmussen, and I. Jungner. "Prevalence of hereditary haemochromatosis in two Swedish urban areas." Journal of internal medicine 225.4 (1989): 249-255. NBER Work Pap Ser [Internet]. 1989;58(58):99–104. Available from: https://www.unhcr.org/publications/manuals/4d9352319/unhcr-protection-training-manual-european-border-entry-officials-2-legal.html?query=excom 1989
9. 9. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology. 2001;33(5):1321–8.
10. 10. Pietrangelo A. Hereditary Hemochromatosis — A New Look at an Old Disease. N Engl J Med. 2004;350(23):2383–97.
11. 11. Pietrangelo A. Non-HFE hemochromatosis. InSeminars in liver disease 2005 Nov (Vol. 25, No. 04, pp. 450-460). Copyright© 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. 2005;25(04):17–9.
12. 12. Koshy A, Mukkada RJ, Chettupuzha AP, Francis J V., Kandathil JC, Mahadevan P. Hemochromatosis in India: First Report of Whole Exome Sequencing With Review of the Literature. J Clin Exp Hepatol [Internet]. 2020;10(2):163–9. Available from: https://doi.org/10.1016/j.jceh.2019.04.051
13. 13. Joshi R, Shvartsman M, Moran E, Lois S, Aranda J, Barque A, et al. Functional consequences of transferrin receptor-2 mutations causing hereditary hemochromatosis type 3. Mol Genet Genomic Med. 2015;3(3):221–32.
14. 14. Bardou-Jacquet E, Brissot P. Diagnostic evaluation of hereditary hemochromatosis (HFE and Non-HFE). Hematol Oncol Clin North Am [Internet]. 2014;28(4):625–35. Available from: http://dx.doi.org/10.1016/j.hoc.2014.04.006
15. 15. Yun S, Vincelette ND. Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis. Crit Rev Oncol Hematol [Internet]. 2015;95(1):12–25. Available from: http://dx.doi.org/10.1016/j.critrevonc.2015.02.006
16. 16. Tembo R. Discussing Why Hemochromatosis is Ignored (A Common but Rarely Diagnosed Disease). Intern Med Res - Open J. 2016;1(1):1–5.
17. 17. Bacon BR, Adams PC, Kowdley K V., Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases.

Hepatology. 2011;54(1):328–43.
18. 18. Porter JL, Rawla P. Hemochromatosis. [Updated 2023 Mar 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430862/. 2024;430862.
19. 19. Pietrangelo A. Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment. Gastroenterology [Internet]. 2010;139(2):393-408.e2. Available from: http://dx.doi.org/10.1053/j.gastro.2010.06.013
20. 20. CLINICAL AND BIOCHEMICAL ABNORMALITIES IN PEOPLE HETEROZYGOUS FOR HEMOCHROMATOSIS Z ANETA J. B ULAJ , M.D., L INDA M. G RIFFEN , B.A., L YNN B. J ORDE , P H .D., C ORWIN Q. E DWARDS , M.D., AND. 2010;(May 1999):1–6.
21. 21. Rorden C, Pratik K. Mutha, Robert L. Sainburg KYH. Differences in Hepatic Phenotype Between Hemochromatosis Patients with HFE C282Y Homozygosity and Other HFE Genotypes. Bone. 2008;23(1):1–7.
22. 22. T R, Jr M. Pathophysiology in Medicine: Hepcidin and iron regulation in health and disease. 1§§. 2014;345(1):57–60.
23. 23. Gandon Y, Olivié D, Guyader D, Aubé C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet (London, England). 2004 Jan;363(9406):357–62.
24. 24. Eschwege E, Saddi R, Wacjman H, Levy R, Thibult N, Duchateau A. [Haemoglobin AIc in patients on venesection therapy for haemochromatosis (author's transl)]. Diabete Metab. 1982 Jun;8(2):137–40.
25. 25. McDermott JH, Walsh CH. Extensive clinical experience: Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab. 2005;90(4):2451–5.
26. 26. Cherfane CE, Hollenbeck RD, Go J, Brown KE. Hereditary hemochromatosis: Missed diagnosis or misdiagnosis? Am J Med [Internet]. 2013;126(11):1010–5. Available from: http://dx.doi.org/10.1016/j.amjmed.2013.07.013
27. 27. Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis [Internet]. 2015;19(1):187–98. Available from: http://dx.doi.org/10.1016/j.cld.2014.09.011
28. 28. Assi TB, Baz E. Current applications of therapeutic phlebotomy. Blood Transfus. 2014;12(SUPPL.1).
29. 29. Porter JB, de Witte T, Cappellini MD, Gattermann N. New insights into transfusion-related iron toxicity: Implications for the oncologist. Crit Rev Oncol Hematol [Internet]. 2016;99(2016):261–71. Available from: http://dx.doi.org/10.1016/j.critrevonc.2015.11.017
30. 30. Kim KH, Oh KY. Indications for therapeutic phlebotomy Polycythemia vera. J Blood Med. 2016;7:139–44.
31. 31. Kontoghiorghes GJ, Spyrou A, Kolnagou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption. Hemoglobin. 2010;34(3):251–64.
32. 32. Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A Review on Iron Chelators in Treatment of Iron. Int J Hematol Stem Cell Res. 2016;10(4):239–47.
33. 33. Kowdley K V., Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, et al. Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. Gastroenterology. 2005;129(2):494–503.
34. 34. McLaren GD, Gordeuk VR. Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Hematology Am Soc Hematol Educ Program. 2009;23(11):195–206.